CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time.

Tuesday, March 25th @ 8:30am ET
Domestic:   1-844-481-2557
International:   1-412-317-0561
Conference ID:   10197392
Webcast:   Webcast Link
     

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Staff

Recent Posts

LabConnect Selects Deloitte to Streamline Financial and Business Operations

JOHNSON CITY, Tenn., June 12, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central…

52 minutes ago

BUDS Technology Transforms Senior Care with AKSSI Virtual Nurse Assistant

ROSWELL, Ga., June 12, 2025 /PRNewswire/ -- Buds Technology, a leading innovator in healthcare solutions, has…

52 minutes ago

Amendola Earns Three Prestigious Healthcare and Health Tech-Focused PR Awards

SCOTTSDALE, Ariz., June 12, 2025 /PRNewswire/ -- Amendola, an award-winning, insights-driven public relations and marketing…

52 minutes ago

Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease

SUMMIT, N.J., June 12, 2025 /PRNewswire/ -- Vascarta Inc., a biopharmaceutical company committed to advancing…

52 minutes ago

Enjoin Earns 2025 Great Place To Work Certification™

The mid-revenue cycle solutions provider announces prestigious award for second consecutive year. NASHVILLE, Tenn., June…

52 minutes ago

Hospital Leaders to Speak at HFMA 2025 Conference on Successful Use of AI in Utilization Management

Experts from Stormont Vail Health will share achievements using MCG artificial intelligence to improve hospital…

53 minutes ago